Bulletin of Environment, Pharmacology and Life Sciences
Bull. Env. Pharmacol. Life Sci., Vol 14[1] December 2024: 09-20

Online ISSN 2277-1808
Journal's URL: http://www.bepls.com
CODEN: BEPLAD

REVIEW ARTICLE **OPEN ACCESS**

Optimization Strategies for Transferosomal Formulation Using Qbd Approach

Priyanka Jhala*, Upendra S. Bhadoriya, Nitin Dubey
Department of M. Pharm (Pharmaceutical Quality Assurance), IPS Academy College of Pharmacy, Indore, 452012, India.
***Corresponding Author:** Priyanka Jhala
Email: priyankajhala99@gmail.com

ABSTRACT
Transferosomes, ultra-deformable vesicular carriers, represent an innovative approach for transdermal drug delivery by enabling efficient penetration through the skin's stratum corneum. They facilitate the delivery of both hydrophilic and lipophilic drugs, enhancing therapeutic outcomes. However, optimizing transferosomal formulations presents challenges due to the intricate interplay between formulation components and processing variables. The Quality by Design (QbD) framework provides a systematic, science-driven approach to address these challenges, ensuring efficient development and consistent performance. Critical quality attributes (CQAs) such as particle size, zeta potential, encapsulation efficiency, deformability, and drug release profiles are key determinants of transferosome efficacy. Formulation parameters, including lipid-to-surfactant ratio, hydration medium type, and processing variables such as sonication and temperature, significantly influence CQAs. Systematic tools like risk assessment and Design of Experiments (DoE) facilitate the optimization of these factors, establishing a robust design space for product quality. Despite challenges related to technical complexity and cost, QbD bridges the gap between innovation and regulatory compliance, leading to advanced and reliable formulations. Future directions involve leveraging artificial intelligence and novel materials to further enhance transferosomal systems, expanding their clinical applications and improving therapeutic efficacy.
Keywords: *Transferosomes, Transferosomal Formulation, QBD Approach, Optimization, Pharmaceutical Quality, Risk assessment in formulation.*

Received 14.10.2024 Revised 18.11.2024 Accepted 26.12.2024

INTRODUCTION

Transferosomes serve as carriers for targeted transdermal drug delivery systems. They are a specialized type of liposome, made up of phosphatidylcholine and an edge activator. This system utilizes phospholipid vesicles as transdermal drug carriers, allowing them to penetrate the stratum corneum either via the intracellular or transcellular route through the creation of an "osmotic gradient." Transferosomes offer several benefits, including the ability to accommodate a wide range of solubilities, improved penetration, biocompatibility, and biodegradability. However, they also have drawbacks, such as susceptibility to oxidative degradation and high production costs. Transferosomes are typically prepared using the conventional rotary evaporation-sonication method, involving phospholipids, surfactants, and the drug. Key evaluation parameters for transferosomes include vesicle size distribution and zeta potential, vesicle morphology, number of vesicles per cubic millimeter, entrapment efficiency, drug content, turbidity, deformability or permeability, penetration ability, occlusion effect, surface charge and charge density, in vitro drug release, in vitro skin permeation studies, and physical stability. Transferosomes have applications in controlled drug release, transportation of large molecular weight compounds, targeted delivery to peripheral subcutaneous tissues, and transdermal immunization.[1] The transdermal route for drug delivery has garnered significant attention in pharmaceutical research, as it avoids many of the issues associated with oral administration. Recently, various methods have been developed to enhance the transdermal delivery of bioactive substances. These include techniques like electrophoresis, iontophoresis, chemical permeation enhancers, microneedles, sonophoresis, and vesicular systems such as liposomes, niosomes, and elastic liposomes like ethosomes and transfersomes. Among these approaches, transfersomes show particular promise. First introduced in the early 1990s, these elastic or deformable vesicles stand out as effective phospholipid-based vesicles for transdermal drug delivery. Due to their ultra-flexible, self-optimizing membranes, transfersomes can deliver drugs consistently either into or through

the skin, depending on how they are applied. These vesicles are more elastic than standard liposomes, making them well-suited for skin penetration. Transfersomes overcome the challenge of skin penetration by squeezing through the intracellular lipid layers of the stratum corneum [2]. The lack of understanding and optimization is often the cause of common sensitivity issues and poor reproducibility in nano-formulations and manufacturing processes. An experimental approach that aids in identifying key parameters and provides insights into their impact on the final product's characteristics and quality would be highly advantageous. To address this, the Quality by Design (QbD) approach has been suggested and endorsed by various industries and regulatory bodies [3,4]. Quality by Design (QbD) begins by defining the Quality Target Product Profile (QTPP), which outlines the key quality attributes (QA) necessary to guarantee the product's safety and effectiveness. These quality attributes are influenced by critical material attributes (CMA) and critical process parameters (CPP). QbD then focuses on identifying, optimizing, and setting specific target values for CMAs and CPPs to ensure the desired QA is met, ultimately achieving the QTPP for the final product. A well-structured experimental design is employed to establish the connection between CMA and CPP and the resulting QA [5,6,7].

Transferosomes

Transferosomes are a unique form of liposomes, made up of phosphatidylcholine and an edge activator. These flexible, soft vesicles are designed to improve the delivery of active compounds [8]. The reason for using vesicles in transdermal drug delivery is based on the fact that they act as drug carriers to deliver entrapped drug molecules across the skin, as well as penetation enhancers because of their composition.[9]



Fig.1. Transferosomes

COMPOSITION AND MECHANISM

A transferosome is a self-adapting, optimized lipid-based aggregate. Surfactant molecules function as "edge activators," giving the transferosomes extreme deformability, which reportedly enables them to pass through channels in the stratum corneum that are smaller than a tenth of their own diameter. According to their inventors, while liposomes struggle to pass through pores smaller than 50 nm, transferosomes as large as 500 nm can spontaneously compress and penetrate the stratum corneum barrier [10,11]. They propose that the primary force behind skin penetration is the "transdermal gradient," which results from the contrast in water content between the relatively dry skin surface (around 20% water) and the nearly fully hydrated viable epidermis (close to 100%).[12] The deformability of transferosomes is attained by incorporating a surface-active agent in the appropriate ratio. The concentration of this agent is critical in transferosome formulation, as at sublytic levels, it imparts flexibility to the vesicle membranes, while at higher concentrations, it leads to the breakdown of the vesicles.[12] Another advantage of the high bilayer deformability in transferosomes is their enhanced capacity to bind and retain water. Being ultra deformable and highly hydrophilic, these vesicles actively avoid dehydration, potentially through a mechanism similar to, but distinct from, forward osmosis. For instance, when a transferosome is applied to an exposed biological surface, like non-occluded skin, it tends to penetrate the barrier and move into the water-rich deeper layers to maintain proper hydration.[12] The use of transferosomes in drug delivery depends on their ability to expand and traverse the hydrophilic pores in the skin or other barriers. Once through, the drug is gradually released from the carrier, allowing the molecules to diffuse and eventually bind to their target. For drugs intended for intracellular action, the transferosome's lipid bilayer may fuse with the cell membrane, unless the vesicle is actively absorbed by the cell through a process known as endocytosis [13,14,15].



Fig.2 The mechanism of action of transfersomes

Currently, the precise mechanism behind enhancing the delivery of active substances into and across the skin is not fully understood. Two proposed mechanisms are:

1. Transferosomes function as drug carriers, maintaining their integrity after penetrating the skin.
2.Transferosomes serve as penetration enhancers by disrupting the highly organized intercellular lipids in the stratum corneum, thereby facilitating the movement of drug molecules through and across this outermost skin layer. [16].

METHODS TO PREPARE TRANSFEROSOMES

Rotary Film evaporation method

The modified hand-shaking method refers to this process, where the API, lecithin, and an edge activator are dissolved in a 1:1 mixture of chloroform and ethanol. This is done by manually shaking the mixture at a temperature above the lipid's transition temperature. The resulting solution is then subjected to evaporation to eliminate the organic solvents. A thin lipid film is left behind and allowed to sit overnight to ensure the complete removal of any remaining solvent. This film is then hydrated by rotating it at 60 RPM for 1 hour at room temperature using a pH 6.5 buffer. The vesicles formed are left to swell for 2 hours at room temperature. The larger vesicles are then reduced to smaller ones through sonication at room temperature. [17,18]



Fig.3 Rotary film evaporation method

Reverse phase evaporation method

This method involves combining lipids and organic solvents in a round-bottom flask while purging the system with nitrogen. An aqueous medium containing edge activators is simultaneously introduced. The drug is incorporated based on its solubility, either into the lipophilic or hydrophilic phase. After sonication, the mixture is left undisturbed for 30 minutes to ensure a uniform blend. The organic phase is then removed under reduced pressure, resulting in a viscous gel that facilitates vesicle formation. [17]

Vortex or sonication method

In this approach, phospholipids and edge activators are uniformly mixed into a phosphate buffer through continuous stirring. Once a milky suspension develops, the mixture undergoes sonication using a bath sonicator and is subsequently extruded through polycarbonate membranes. [18]

Ethanol Injection Method

This method provides significant advantages over others. In this process, the drug is dissolved in a water solution and heated to a steady temperature while being continuously stirred. Phospholipids and edge activators are then combined with an ethanolic solution in an aqueous medium to initiate the reaction. [19,20]



Fig.4 Ethanol in injection method

Freeze thaw method

In this process, the multilamellar vesicle suspension is frozen and transferred into a tube, where it is immersed in a nitrogen bath at -300°C for 30 seconds. Once frozen, the suspension is heated in a water bath, and this freeze-thaw cycle is repeated for 8-9 rounds. [18,20,21]



Fig.5 Freeze thaw method

Materials commonly used for the preparation of transferosomes:

Various excipients are used in the formulation of transferosomes to achieve desired vesicle properties. These materials play specific roles such as vesicle formation, flexibility, hydration, and visualization. The commonly used ingredients are summarized in Table 1. [1]

Table 1: Ingredients Commonly Used in the Preparation of Transferosomes with Their Functions

Ingredient	Examples	Functions
Phospholipid	Soya Phosphatidylcholine Egg Phosphatidylcholine Disteryl Phosphatidylcholine	Vesicle forming Component
Surfactant	Sodium Cholate Sodium deoxy Cholate Tween 80 Span 80	For Providing Flexibility

Alcohol	Ethanol Methanol	As a Solvent
Dye	Rhodamine-123 Rhodamine-DHPE Flurescein-DHPE Nil red 6Corboxy fluorescence	For Confocal Scaning Laser Microscopy (CSLM) Study
Buffering Agent	Saline phosphate buffer (PH 6.5) 7% v/v ethanol Tris buffer (PH 6.5)	As a hydrating medium

Characterization of transferosomes

The characterization of transferosomes is essential to evaluate their physicochemical properties, stability, and performance. Various analytical techniques are employed to assess parameters such as vesicle morphology, size distribution, entrapment efficiency, and drug release behavior. The commonly used methods are summarized in Table 2. [22]

Table 2: Common Parameters and Analytical Methods Used for the Characterization of Transferosomes

Parameter	Method
Vesicle shape morphology	Transmission electron microscopy
Entrapment efficiency	Mini column centrifugation method
Vesicle size and size distribution	Dynamic light scattering method
Skin permeation potential	Confocal laser scanning microscopy
Phospholipid surfactant interaction	Fluorescence microscopy
Degree of deformability	Transmission electron microscopy
Surface charge and charge density	Thin layer chromatography
Turbidity	31P NMR
In vitro drug release study	Differential scanning calorimeter Extrusion method
Effect on skin structure	Zeta meter Nephelometer
Stability study	Side by side diffusion diffusion cell with artificial or biological membrane, dialysis bag diffusion Histological studies Transmission electron microscopy Dynamic light scatterimg method

Quality by Design (QbD)

QbD in Pharmaceutical Products

The primary goal of the pharmaceutical industry is to deliver high-quality pharmaceutical products. Ensuring quality involves addressing all factors that could influence the efficacy and safety of prescribed medications, directly impacting patient health. Historically, the Quality by Testing (QbT) approach was the standard method for quality assurance. This method focused on in-process testing of raw materials, intermediates, and final products to verify their quality during manufacturing. However, the pharmaceutical sector has since shifted towards an alternative strategy that ensures product quality is built into the design phase, while still incorporating the essential quality control tests of QbT. [23]. This modern approach, known as Quality by Design (QbD), emphasizes developing and manufacturing pharmaceutical products based on predefined quality attributes. QbD aims to minimize the need for extensive in-process or post-production testing, while improving reproducibility, manufacturability, efficacy, and safety. International regulatory bodies such as the ICH, US FDA, and EMA have established clear guidelines for implementing QbD, demonstrating a global commitment to consistently producing high-quality pharmaceutical products. [7,24,25]

Tools and Key Elements of QbD

Generally, there are four key elements of the QbD:

(i) The Quality Target Product Profile (QTPP),
(ii) Critical Quality Attributes (CQAs),
(iii) Critical Material Attributes (CMAs),
(iv) Critical Process Parameters (CPPs).

These elements work together in a step-by-step approach to form the foundation of the QbD strategy.



Fig.6 The pharmaceutical development guidelines suggested by ICH, US FDA and EMA to outline the QbD key elements [7]

Variables used in formulation

Independent Variables (CMAs/CPPs): These are formulation components (critical material attributes) or process conditions (critical process parameters) that can be adjusted during development.

Dependent Variables (CQAs): These are the measurable outcomes or properties of the transferosomal formulation that directly influence product quality, performance, and efficacy.

Dependent and Independent variables commonly used in transferosome formulations:

In transferosome formulation, both critical quality attributes (CQAs) and critical material/process parameters (CMAs/CPPs) play a vital role. Understanding the relationship between dependent and independent variables is essential for optimizing formulation performance. Table 3 summarizes these key variables. [26,27,28]

Table 3: Commonly Used Dependent and Independent Variables in Transferosome Formulations

S.no.	Dependent variable (CQAs)	Independent variable (CMAs and CPPs)
1.	Particle size, encapsulation efficiency	Lipid-to-Surfactant Ratio
2.	Stability, deformability	Type of Phospholipid (e.g., PC or SPC)
3.	Entrapment efficiency, deformability index	Surfactant Type (e.g., Span, Tween)
4.	Drug loading, release rate	Drug-to-Lipid Ratio
5.	Encapsulation efficiency, stability	Hydration Medium (e.g., pH, ionic strength)
6.	Particle size, zeta potential	Sonication Time and Intensity
7.	Drug entrapment, vesicle aggregation	Hydration Time (Hime)
8.	Particle stability, drug retention	Temperature During Hydration
9.	Uniformity of vesicle size, encapsulation	Solvent Evaporation Conditions

Identifying CQAs for Transferosomal Formulation

Critical Quality Attributes (CQAs) are essential for ensuring the consistent quality, safety, and efficacy of transferosomal formulations. According to research, the following CQAs are commonly identified:[29]

The following table no.4 provides a concise overview of the essential CQAs for transferosomal formulations, highlighting their significance in ensuring high-quality, effective, and stable transdermal drug delivery systems. [30,31,32]

Table 4: Critical Quality Attributes (CQAs) of Transferosomal Formulations and Their Impact on Product Performance

CQA	Description	Impact on Product
Particle Size	Average size of the vesicles in the formulation.	Influences skin penetration, stability, and drug delivery efficiency.
Polydispersity Index (PDI)	Measure of size distribution uniformity among vesicles.	A lower PDI indicates a uniform and reproducible formulation.
Zeta Potential	Surface charge of vesicles, measured in mV.	Affects colloidal stability and skin interaction.
Entrapment Efficiency (%EE)	Percentage of drug encapsulated in the vesicles.	Determines drug loading capacity and therapeutic efficacy.
Deformability Index	Flexibility of vesicles to pass through micropores or skin barriers.	Enhances skin permeability and ensures efficient drug delivery.
In Vitro Drug Release	Rate and mechanism of drug release from the formulation.	Affects therapeutic outcomes and dosing frequency.
Skin Permeation Efficiency	Ability of the formulation to deliver drugs across the skin layers.	Determines the bioavailability of the drug at the target site.
Physical Stability	Resistance of vesicles to changes in environmental conditions like temperature and humidity.	Impacts the shelf life and usability of the formulation.
Drug Leakage Stability	Assessment of drug retention within vesicles during storage.	Ensures formulation stability and therapeutic consistency.

Identifying Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs) in Transferosomal Formulation Development

Critical Material Attributes (CMAs) significantly affect the quality and performance of transferosomal formulations. Understanding how these raw material properties influence CQAs is essential for effective formulation development. Table 5 summarizes key CMAs and their impact. [31,32]

Table 5: Critical Material Attributes (CMAs) and Their Impact on Critical Quality Attributes (CQAs) in Transferosomal Formulations

CMA	Impact on CQAs
Type of Phospholipid	Affects vesicle stability, drug encapsulation, and skin permeation efficacy.
Lipid-to-Surfactant Ratio	Controls vesicle deformability and entrapment efficiency.
Surfactant Type	Influences vesicle formation, deformability, and drug release profile.
Hydration Medium	Affects particle size and entrapment efficiency.
Drug Properties	Solubility, partition coefficient, and stability dictate encapsulation and release behavior.

Critical Process Parameters (CPPs) are key variables in the manufacturing process that must be carefully controlled to ensure consistent product quality. These parameters directly influence Critical Quality Attributes (CQAs) of transferosomal formulations. Table 6 highlights important CPPs and their impact.

Table 6: Critical Process Parameters (CPPs) and Their Impact on Critical Quality Attributes (CQAs) in Transferosomal Formulations

CPP	Impact on CQAs
Hydration Time	Influences vesicle formation, size distribution, and drug entrapment efficiency.
Sonication Time	Reduces vesicle size, improving skin penetration but may affect drug entrapment.
Temperature	Affects lipid phase behavior and vesicle deformability.
Rotary Evaporation Speed	Influences lipid film formation, impacting vesicle size and uniformity.
Hydration Volume	Impacts vesicle size, encapsulation efficiency, and overall drug release profile.

Combined Impact on CQAs

The combined influence of Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs) on Critical Quality Attributes (CQAs) determines the overall performance of transferosomal formulations. Table 7 illustrates how these factors interact to impact product quality. [31,32]

Table 7: Combined Impact of CMAs and CPPs on CQAs and Their Influence on Transferosomal Product Performance

CQA Influencing	Influencing CMA	Influencing CPP	Resulting Product Impact
Particle Size	Lipid composition, surfactant type	Sonication time, homogenization	Smaller size improves skin permeation.
Entrapment Efficiency	Phospholipid type, drug solubility	Hydration time, temperature	Higher efficiency ensures adequate drug loading.
Deformability	Lipid-to-surfactant ratio	Hydration temperature	High deformability ensures effective skin penetration.
Drug Release Profile	Drug solubility, surfactant type	Hydration conditions	Controlled release enhances therapeutic efficacy.

Critical Quality Attributes (CQAs) of transferosomes are the measurable physical, chemical, biological, or microbiological properties or characteristics that directly influence the efficacy, safety, and quality of the drug delivery system. Below are the key CQAs for transferosomes, explained briefly: [33,34,35]

Particle Size

Impact: Smaller particles enhance skin penetration and improve bioavailability, while larger particles may remain on the surface. Particle size affects the stability and homogeneity of the formulation.[33]

Research Evidence: A study on transferosomes loaded with curcumin demonstrated that optimizing particle size (100–200 nm) improved skin permeation and therapeutic effects.

Polydispersity Index (PDI)

Impact: PDI measures the uniformity of particle size distribution. A lower PDI (<0.3) indicates homogeneity, which is critical for consistent drug delivery.

Research Evidence: Formulations with a low PDI exhibited higher stability and reproducibility during long-term storage. [33,34]

Zeta Potential

Impact: Indicates the surface charge and stability of vesicles. High zeta potential (positive or negative) prevents aggregation, ensuring colloidal stability.

Research Evidence: Studies showed that transferosomes with zeta potential >30 mV or < -30 mV had enhanced stability during storage.

Encapsulation Efficiency (EE%)

Impact: Reflects the percentage of drug successfully encapsulated in vesicles. Higher EE% ensures effective drug delivery and reduces wastage.

Research Evidence: Transferosomal formulations of diclofenac achieved >90% EE, enhancing its sustained release and anti-inflammatory activity.

Deformability Index

Impact: A higher deformability index indicates better vesicle flexibility, allowing them to penetrate deeper skin layers through narrow pores.

Research Evidence: Transferosomes optimized for high deformability demonstrated superior transdermal delivery compared to conventional liposomes.

Drug Release Profile

Impact: Determines the rate and extent of drug release. Controlled and sustained release ensures prolonged therapeutic action.

Research Evidence: Formulations with optimized lipid-to-surfactant ratios exhibited a sustained release profile over 24 hours, improving patient compliance.

Stability

Impact: Stability ensures that vesicles maintain their integrity, size, and encapsulated drug over the product's shelf life.

Research Evidence: Use of antioxidants and cryoprotectants in formulation improved stability against oxidative degradation.

Risk Assessment in QbD Framework

Risk assessment is a key element of the Quality by Design (QbD) approach in pharmaceutical development. It systematically identifies, evaluates, and mitigates potential risks that may impact the quality of the product. Below are the core aspects of risk assessment within the QbD framework: [36,37]

Importance of Risk Assessment

Risk assessment helps in determining the critical material attributes (CMAs) and critical process parameters (CPPs) that impact critical quality attributes (CQAs).

It ensures a science-based approach to product development and aligns with regulatory guidelines like ICH Q8(R2), Q9, and Q10.

Tools for Risk Assessment

Common tools used for risk assessment include:

Ishikawa (Fishbone) Diagram: Identifies root causes of potential risks by categorizing factors (e.g., material, process, equipment).

Failure Mode and Effects Analysis (FMEA): Assesses the likelihood, severity, and detectability of risks and assigns a risk priority number (RPN) for mitigation prioritization.

Pareto Analysis: Highlights the most significant contributors to potential risks.

Risk Ranking and Filtering: Simplifies the evaluation of factors based on their potential impact on CQAs.

Steps in Risk Assessment

1.Risk Identification: Recognize potential CMAs and CPPs that might affect CQAs (e.g., lipid concentration or sonication time in transferosome formulation).

2.Risk Analysis: Evaluate the relationship between variables and their impact on product quality.

Use tools like design of experiments (DoE) for detailed analysis.

3. Risk Evaluation: Prioritize risks based on their severity and probability, guiding focus areas for optimization.

4. Risk Control and Mitigation: Apply process controls, monitoring, or parameter adjustments to minimize high-priority risks.

5. Application in Transferosome Formulation- In transferosome development, risk assessment is used to evaluate factors such as:

- Lipid-to-surfactant ratio (CMA): Impacts encapsulation efficiency and deformability.
- Hydration time (CPP): Affects particle size and stability.
- Sonication conditions (CPP): Determines vesicle size and polydispersity.

Example: FMEA can prioritize factors where hydration medium pH has a higher RPN due to its critical role in maintaining drug stability.

6. Benefits of Risk Assessment in QbD:

- Enhances process understanding and robustness.
- Reduces trial-and-error approaches, saving time and resources.
- Aligns product development with regulatory expectations, ensuring smoother approval processes.

Key Challenges in Transferosomal Formulation

Key challenges in the formulation of transferosomes, as highlighted in research, often involve the complex interplay of formulation and process parameters, which impact their performance and scalability. Below are some key challenges discussed in studies:

Stability Issues: Transferosomes are prone to aggregation, fusion, or leakage during storage, which can compromise drug efficacy. Stability optimization requires selecting appropriate lipids and surfactants.

Batch-to-Batch Variability: Ensuring uniformity in vesicle size, entrapment efficiency, and deformability during production poses significant difficulties. This necessitates precise control over formulation and process variables.

Skin Permeation Efficiency: Achieving consistent penetration across various skin types depends on the selection of penetration enhancers, lipid composition and surfactant ratios.

Drug Loading and Release Kinetics: High drug loading often leads to vesicle instability, while controlled drug release requires fine-tuning of vesicle composition.

Manufacturing Scalability: Transitioning from lab-scale to large-scale production is complex, especially in maintaining the physicochemical properties of transferosomes.

Cost-Effectiveness: The use of high-purity lipids and surfactants increases production costs, posing challenges for commercialization.

Regulatory Compliance: Developing a formulation that meets stringent regulatory standards for quality, safety, and efficacy adds an additional layer of complexity**.** [38,39]

14. Design of Experiment in Transferosomal Formulation

Advantages of DoE -

Efficiency: Reduces the number of experiments while maximizing information gain.

Insights into Interactions: Identifies synergistic or antagonistic effects between variables.

Robust Optimization: Ensures consistent quality by focusing on critical parameters.

Scalability: Results guide both small-scale and industrial production processes.

Examples of DoE Applications in Transferosomal Formulations

Study on lipid to surfactant ratio: Using a **Box-Behnken Design**, researchers optimized lipid and surfactant concentrations to achieve high encapsulation efficiency and deformability while minimizing vesicle size.

Optimization of hydration time and temperature: A **Central Composite Design** was employed to study the effect of hydration parameters on particle size and drug release.

Analysis of sonication condition: Using **Fractional Factorial Design**, experiments explored the influence of sonication amplitude and time on polydispersity index and zeta potential.

Future Directions and Challenges in Transferosomal Formulation Using QbD Approach [31,42,43]

The application of the QbD framework in transferosomal formulations has led to significant advancements in drug delivery. However, several challenges and future opportunities need to be addressed to further refine and expand this technology. [40,41]

Future Directions

a. Advancements in Analytical Tools

Development of advanced characterization techniques, such as atomic force microscopy (AFM) and real-time particle tracking, will enable better understanding of transferosomal properties.

Integration of artificial intelligence (AI) and machine learning (ML) for predictive modeling can accelerate optimization and reduce experimental workloads.

b. Exploration of New Excipients

Introduction of novel lipids and surfactants with enhanced biocompatibility and functionality can improve transferosome stability and efficacy.

Natural and biodegradable materials are being explored to reduce toxicity risks.

c. Personalized Medicine

Incorporating QbD principles into personalized drug delivery systems can address patient-specific needs, tailoring formulations based on individual genetic or disease profiles.

d. Regulatory Harmonization

Standardization of QbD practices across regulatory bodies will streamline product approval processes and encourage broader adoption in the industry.

e. Applications in New Therapeutic Areas

Expansion into novel therapeutic areas, including biologics (peptides, proteins, and vaccines), offers immense potential for systemic and localized drug delivery.

Challenges

a. Complexity of Transferosomal Systems

Transferosomes involve multifactorial interactions between formulation components and process parameters, making them challenging to model accurately.

Identifying all critical quality attributes (CQAs) and their interdependencies remains complex.

b. Scalability and Manufacturing

Scaling up transferosomal formulations from laboratory to industrial scale without compromising quality remains a bottleneck.

High energy requirements for processes like sonication and homogenization can be cost-intensive and difficult to replicate consistently.

c. Regulatory Concerns

Lack of specific regulatory guidelines for transferosomes complicates their approval pathway.

Demonstrating batch-to-batch consistency while using flexible vesicular systems poses challenges.

d. Stability Issues

Transferosomal formulations are prone to physical instability, such as aggregation or vesicle leakage, leading to reduced shelf life.

Incorporating stabilizers often adds to the complexity of the system.

e. Skin Permeation Limitations

Variability in skin properties (age, hydration, thickness) across populations can lead to inconsistent therapeutic outcomes.

Achieving effective delivery of large molecules like peptides and proteins remains a challenge.

Bridging Challenges and Opportunities

Collaborative Research: Partnerships between academia and industry can drive innovation in formulation techniques and equipment.

Regulatory Dialogue: Engaging with regulatory authorities to develop clear guidelines for vesicular systems.

Investment in Training: Equipping researchers with advanced knowledge of QbD tools, like risk assessment and design of experiments (DoE), to enhance formulation strategies.

Green Manufacturing: Employing eco-friendly techniques to ensure sustainable production processes.

DISCUSSION OR CONCLUSION

The QbD framework not only improves formulation robustness but also aligns with regulatory expectations, promoting a quality-first approach in drug development. Despite its advantages, implementing QbD comes with challenges such as the need for technical expertise, time investment, and

complex data analysis. Future research should focus on automating QbD processes through artificial intelligence (AI) and machine learning (ML) to streamline optimization and predictive modeling. The exploration of novel lipids, surfactants, and techniques such as microfluidics could further enhance the performance of transferosomes. Challenges such as scale-up difficulties, cost constraints, and ensuring product stability during storage require ongoing innovation. By addressing these issues, QbD can remain a cornerstone for developing next-generation nanocarriers. The journey towards fully optimized transferosomal formulations demands a multidisciplinary approach, bridging pharmaceutical sciences, engineering, and data analytics. QbD, when leveraged effectively, has the potential to revolutionize the field, creating drug delivery systems that are not only effective but also economically and environmentally sustainable.

REFERENCES

1. Solanki D, Kushwah L, Motiwale M, Chouhan V. (2016): Transferosomes-a review. World journal of pharmacy and pharmaceutical sciences. Aug 12;5(10):435-49.
2. Sachan R, Parashar T, Singh V, Singh G, Tyagi S, Patel C, Gupta A. (2013): Drug carrier transfersomes: A novel tool for transdermal drug delivery system. International Journal of Research and Development in Pharmacy and Life Sciences. Feb;2(2):309-16.
3. Tefas LR, RUS L, Achim M, Vlase L, tomuţă i. (2018): Application of the quality by design concept in the development of quercetin-loaded polymeric nanoparticles. Farmacia. Sep 1;66(5).
4. Sangshetti JN, Deshpande M, Zaheer Z, Shinde DB, Arote R. (2017): Quality by design approach: Regulatory need. Arabian Journal of chemistry. May 1;10:S3412-25.
5. Yu LX. (2008): Pharmaceutical quality by design: product and process development, understanding, and control. Pharmaceutical research. Apr;25:781-91.
6. Eon-Duval, Alex, et al. (2012): "Application of the quality by design approach to the drug substance manufacturing process of an Fc fusion protein: Towards a global multi-step design space." Journal of pharmaceutical sciences 101.10 : 3604-3618.
7. Alshaer, Walhan, et al. (2022): "Quality by design approach in liposomal formulations: Robust product development." Molecules 28.1: 10.
8. Cevc, Gregor, and Gabriele Blume.(2001): "New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes." Biochimica et biophysica acta (BBA)-biomembranes 1514.2: 191-205.
9. Vyas SP, Khar RK. 1st Ed. Delhi: CBS Publishers; 2002. delivery Targeted and controlled drug; pp. 219–43.
10. Kurhe, Snehal Arjun, Kedar Bavaskar, and Ashish Jain. (2022): "Transferosome: a vesicular transdermal delivery system for enhanced drug permeation." : 206-210.
11. Chuanping N. (2010): College of pharmacy liaoning medical university. preparation and study on properties of ibuprofen transferosomes. J Math Med.:2. [Google Scholar]
12. Shen Y, Zhang Y, Liao Ming. (2007): Preparation and quality evaluation of drug loading transferosomes. Med J Chin People's Liberation Army. :10. [Google Scholar]
13. Vyas SP, Khar RK. (2002): 1st Ed. Delhi: CBS Publishers; Targeted and controlled drug delivery; pp. 219–43.
14. Langer R. (2004): Transdermal drug delivery: Past progress, current status, and future prospects. Adv Drug Deliv Rev.. ;56:557–8
15. Transferosomes- accessed on https://encyclopedia.pub/entry/2142.
16. Maurya SD, Aggarwal S, Tilak VK, Dhakar RC, Singh A, Maurya G. (2010): Enhanced transdermal delivery of indinavir sulfate via transfersomes. Maurya Sheo Datta et al./Pharmacie Globale (IJCP). 2010;1(06).
17. Marwah H, Garg T, Rath G, Goyal AK. (2016): Development of transferosomal gel for trans-dermal delivery of insulin using iodine complex. Drug delivery. Jun 12;23(5):1636-44.
18. Kumar PK, Kumar RS. (2021): Review on transferosomes and transferosomal gels. Journal of Pharmaceutical Research International. Sep 9;33(43B):114-26.
19. Tiwari P, Alagusundaram M, Mishra N, Bhattacharya V. Effective targeted drug delivery system an review of transferosome.
20. Patel NN, Vikran KR, Gupta A, Gupta A. (2013): Proniosomes for improved transdermal drug delivery–A review. The Pharma, a Journal of Pharmacy Research.; 4:42-8.
21. Chaurasiya P, Ganju E, Upmanyu N, Ray SK, Jain P. (2019): Transfersomes: a novel technique for transdermal drug delivery. Journal of drug delivery and therapeutics. Jan 15;9(1):279-85.
22. Rajan R, Jose S, Mukund VB, Vasudevan DT. (2011): Transferosomes-A vesicular transdermal delivery system for enhanced drug permeation. Journal of advanced pharmaceutical Technology & Research. 2011 Jul 1;2(3):138-43.
23. Rogerson WP. (1983): Reputation and product quality. The Bell Journal of Economics. Oct 1:508-16.
24. Zhang L, Mao S. (2017): Application of quality by design in the current drug development. Asian journal of pharmaceutical sciences. Jan 1;12(1):1-8.
25. ICH Q10 Pharmaceutical quality system - Scientific guideline accessed on https://www.ema.europa.eu/en/ich-q10-pharmaceutical-quality-system-scientific-guideline
26. Bhattacharyya S, Lakshmanan KT, Muthukumar A. (2024): Formulation and Evaluation of a Transferosomal Gel of Famciclovir for Transdermal Use. Turk J Pharm Sci. Sep 2;21(4):303-12.

27. Ahmed TA. (2015): Preparation of transfersomes encapsulating sildenafil aimed for transdermal drug delivery: Plackett–Burman design and characterization. Journal of liposome research. Jan 2;25(1):1-0.
28. Ezzeldeen Y, Swidan S, ElMeshad A, Sebak A. (2021): Green synthesized honokiol transfersomes relieve the immunosuppressive and stem-like cell characteristics of the aggressive B16F10 melanoma. International Journal of Nanomedicine. Aug 24:5693-712.
29. Opatha SA, Titapiwatanakun V, Chutoprapat R. (2020): Transfersomes: A promising nanoencapsulation technique for transdermal drug delivery. Pharmaceutics. Sep;12(9):855.
30. Yenduri G, Costa AP, Xu X, Burgess DJ. (2022): Impact of critical process parameters and critical material attributes on the critical quality attributes of liposomal formulations prepared using continuous processing. International Journal of Pharmaceutics. May 10;619:121700.
31. Fernández-García R, Lalatsa A, Statts L, Bolás-Fernández F, Ballesteros MP, Serrano DR. (2020): Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale. International journal of pharmaceutics. Jan 5;573:118817.
32. Matharoo N, Mohd H, Michniak-Kohn B. (2024): Transferosomes as a transdermal drug delivery system: Dermal kinetics and recent developments. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. Jan;16(1):e1918.
33. Little TA. (2018): Identifying and Controlling CPPs and CMAs Statistical methods to identify critical process parameters and critical material attributes-and approaches to control them-are needed to protect drug product and drug substances. Biopharm international. Mar 1;31(3):38-43.
34. Sansare S, Duran T, Mohammadiarani H, Goyal M, Yenduri G, Costa A, Xu X, O'Connor T, Burgess D, Chaudhuri B. (2021): Artificial neural networks in tandem with molecular descriptors as predictive tools for continuous liposome manufacturing. International Journal of Pharmaceutics. Jun 15; 603:120713.
35. Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, Woodcock J. (2014): Understanding pharmaceutical quality by design. The AAPS journal. Jul; 16:771-83.
36. Ojha A, Bhargava S. (2022): International council for harmonisation (ICH) guidelines. In Regulatory affairs in the pharmaceutical industry Jan 1 (pp. 47-74). Academic Press.
37. Trivedi B. (2012): Quality by design (qbd) in pharmaceuticals. International Journal of Pharmacy and Pharmaceutical Sciences. ;4(1):17-29.
38. Chaurasia L, Singh S, Arora K, Saxena C. (2019): Transferosome: A suitable delivery system for percutaneous administration. Current Research in Pharmaceutical Sciences. Apr 8:1-1.
39. Bnyan R, Khan I, Ehtezazi T, Saleem I, Gordon S, O'Neill F, Roberts M. (2019): Formulation and optimisation of novel transfersomes for sustained release of local anaesthetic. Journal of Pharmacy and Pharmacology. Oct;71(10):1508-19.
40. Montgomery DC. (2017): Design and analysis of experiments. John wiley & sons.
41. Gayathri H, Sangeetha S. (2022): Design and development of tofacitinib citrate loaded transferosomal gel for skin cancer by box-Behnken design-doe approach. Int. J. Health Sci.; 6:3119-40.
42. Das Kurmi B, Tekchandani P, Paliwal R, Rai Paliwal S. (2017): Transdermal drug delivery: opportunities and challenges for controlled delivery of therapeutic agents using nanocarriers. Current drug metabolism. May 1;18(5):481-95.
43. Aru PB, Gulhane MS, Katekar VA, Deshmukh SP. (2024): Quality by Design (QbD) in pharmaceutical development: A comprehensive review. GSC Biological and Pharmaceutical Sciences.;26(1):328-40.

CITATION OF THIS ARTICLE

Priyanka Jhala, Upendra S. Bhadoriya, Nitin Dubey. Optimization Strategies for Transferosomal Formulation Using Qbd Approach. Bull. Env. Pharmacol. Life Sci., Vol 15[1] January 2025: 09-20